Thursday, September 19, 2013
Despite the striking efficacy of chimeric antigen receptor-based T
cell therapies in small clinical trials in patients with leukemia, the ability
to rapidly provide T cells to a large number of recipients is limited by the
lack of readily available tumor antigen-associated human T lymphocytes. To
tackle this problem, a Memorial Sloan-Kettering Cancer Center team has
incorporated patient-derived induced pluripotent stem cells into an
immunotherapy protocol to provide large-scale production of T cells endowed
with enhanced antitumor properties.1
Jianxun Song, assistant professor of
microbiology and immunology at Pennsylvania State University Hershey College of Medicine, said that key next steps would be to show safety and
simplify the approach, regardless of whether iPS cells are used to generate
allogeneic or autologous T cells.
T. SciBX 6(36);
Published online Sept. 19, 2013
1. Themeli, M. et al.
Nat. Biotechnol.; published online Aug.11, 2013; doi:10.1038/nbt.2678
Contact: Michel Sadelain, Memorial Sloan-Kettering Cancer Center, New
2. Brentjens, R.J. et
al. Sci. Transl. Med. 5, 177ra138 (2013)
3. Lei, F. et al.
Cancer Res. 71, 4742-4747 (2011)
AND INSTITUTIONS MENTIONED
Kite Pharma Inc., Los Angeles, Calif.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Pennsylvania State University Hershey College of Medicine, Hershey, Pa.